MESNA
Reading File
MESNA (sodium 2-mercaptoethanesulfonate) is a uroprotective agent used to prevent hemorrhagic cystitis caused by oxazaphosphorine alkylating agents (cyclophosphamide, ifosfamide). It works by binding and inactivating acrolein - the toxic urothelial metabolite - in the urinary tract.
Searching sources...
Finding Sources
Searching PubMed
mesna uroprotection hemorrhagic cystitis
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Here is a comprehensive overview of MESNA:
MESNA (Sodium 2-Mercaptoethanesulfonate)
What Is It?
MESNA is a synthetic sulfhydryl (thiol) compound used as a uroprotective agent to prevent urothelial toxicity caused by oxazaphosphorine alkylating drugs - primarily ifosfamide and high-dose cyclophosphamide. The name is an acronym for MErcaptoSodium e-Acidic (or derived from its chemical name). Its trade name is Mesnex.
Mechanism of Action
Cyclophosphamide and ifosfamide undergo hepatic metabolism. The key toxic metabolite is acrolein (an alpha,beta-unsaturated aldehyde), which accumulates in urine and directly damages urothelial cells, causing hemorrhagic cystitis and, with prolonged exposure, bladder cancer.
How MESNA works:
- MESNA is administered IV or orally and rapidly oxidized in the plasma to its inactive disulfide form, dimesna
- Dimesna is filtered at the glomerulus and concentrated in the renal tubules
- In the urinary tract, dimesna is reduced back to the active free thiol (MESNA)
- The free thiol group (-SH) of MESNA binds covalently to acrolein in the urine, forming a stable, non-toxic thioether complex
- This inactivates acrolein locally in the urine without affecting systemic antitumor activity
This is the key elegance of MESNA: it acts as a urinary-tract-specific detoxifier. It does NOT interfere with the antineoplastic effects of cyclophosphamide or ifosfamide in the blood or tumors.
Clinical Uses
| Indication | Notes |
|---|---|
| Ifosfamide-induced hemorrhagic cystitis (primary, approved indication) | Mandatory co-administration with all ifosfamide regimens |
| High-dose cyclophosphamide (e.g., transplant conditioning, HSCT) | Standard of care; less clear benefit with low-dose oral cyclophosphamide |
| Rheumatologic use (pulse IV cyclophosphamide for vasculitis, SLE, Wegener's) | Widely used; RCT data from oncology extrapolated |
| Endoscopy adjunct | MESNA injected submucosally softens connective tissue (used in ESD procedures) |
Dosing
With Ifosfamide (Standard Regimen):
- IV bolus protocol: MESNA dose = 20% of ifosfamide dose, given at time 0, +4 h, and +8 h → total MESNA = 60% of ifosfamide dose
- Alternative: Single MESNA dose equal to 100% of ifosfamide dose given concomitantly
- Patients should also receive at least 2 L of oral or IV fluid daily
- Treatment cycles repeated every 3-4 weeks
With High-Dose Cyclophosphamide:
- Administered IV concomitantly; dosing varies by protocol
- For daily oral cyclophosphamide: oral MESNA given three times daily (though rarely used due to disagreeable taste)
Pharmacokinetics
- IV administration: rapidly oxidized to dimesna (inactive) in blood; selectively reduced back to MESNA in the urinary tract
- Oral bioavailability: approximately 45-79% (variable)
- Plasma half-life: short (about 1.2 h for MESNA, 70 h for dimesna)
- The short t½ is why multiple dosing or continuous infusion is needed to maintain protection throughout the period of urotoxic metabolite excretion
- Renal excretion is the primary route
Adverse Effects
MESNA is generally well tolerated. Reported adverse effects include:
- Nausea, vomiting, diarrhea (more common with oral form)
- Disagreeable taste with oral formulation (major limitation to oral use)
- Hypersensitivity reactions (rare)
- False-positive urine ketone test: MESNA contains free sulfhydryl groups that cross-react with nitroprusside-based urine dipstick tests (clinically important to know)
Important Clinical Points
- Does NOT protect against other toxicities of cyclophosphamide/ifosfamide (myelosuppression, nephrotoxicity, CNS effects from ifosfamide - which is managed with methylene blue)
- MESNA + IV hydration is the standard prophylaxis; hydration alone is insufficient for high-dose regimens
- For ifosfamide specifically, MESNA co-administration is considered mandatory; bladder toxicity was the original dose-limiting factor that restricted ifosfamide's use
- The evidence base for MESNA's efficacy comes primarily from ifosfamide studies and animal models; rheumatology data are supportive but less robust
- Bladder cancer risk from long-term cyclophosphamide is not fully mitigated by MESNA alone - treatment duration should be minimized
Sources:
- Goodman & Gilman's Pharmacological Basis of Therapeutics (Ch. 70 - Alkylating Agents)
- Firestein & Kelley's Textbook of Rheumatology (Urologic toxicity, Alkylating Agents sections)
- Lippincott Illustrated Reviews: Pharmacology
drugs used to ameliorate toxicities due to anti cancer drugs
Reading File
This is a broad topic. Key agents include MESNA (urotoxicity), leucovorin (methotrexate toxicity), amifostine (cisplatin nephrotoxicity), dexrazoxane (doxorubicin cardiotoxicity), filgrastim (myelosuppression), ondansetron (nausea), and allopurinol (tumor lysis). Let me pull comprehensive textbook data across all these categories.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Drugs Used to Ameliorate Toxicities of Anticancer Drugs
These are "cytoprotective" or "chemoprotective" agents - drugs that reduce the adverse effects of chemotherapy without diminishing antitumor efficacy.
1. MESNA - Urotoxicity (Hemorrhagic Cystitis)
| Property | Detail |
|---|---|
| Anticancer drug | Cyclophosphamide, Ifosfamide |
| Toxicity prevented | Hemorrhagic cystitis (due to acrolein metabolite) |
| Mechanism | Free thiol group binds and inactivates acrolein in the urine; acts locally in urinary tract only |
| Dosing (ifosfamide) | 20% of ifosfamide dose IV at 0 h, +4 h, +8 h (total = 60%); or single dose equal to 100% of ifosfamide dose |
| Note | Does NOT interfere with antitumor activity; oral form has disagreeable taste |
- Goodman & Gilman's Pharmacological Basis of Therapeutics
2. LEUCOVORIN (Folinic Acid) - Myelosuppression & GI Toxicity
| Property | Detail |
|---|---|
| Anticancer drug | Methotrexate (high-dose); also used with 5-FU |
| Toxicity prevented | Bone marrow toxicity and GI mucositis |
| Mechanism | Leucovorin is an active (reduced) form of folate - bypasses the DHFR enzyme block caused by methotrexate, allowing normal cells to resume folate metabolism |
| Use | "Leucovorin rescue" - given within 24 h after high-dose MTX infusion; 15 mg/m² rescues from 10⁻⁸-10⁻⁶ M MTX with normal renal function |
| Note | Pemetrexed and pralatrexate require folic acid + vitamin B12 supplementation to reduce hematologic/GI toxicities |
- Lippincott Illustrated Reviews: Pharmacology; Brenner & Rector's The Kidney
3. DEXRAZOXANE - Cardiotoxicity
| Property | Detail |
|---|---|
| Anticancer drug | Doxorubicin (anthracyclines) |
| Toxicity prevented | Anthracycline-induced cardiomyopathy / heart failure |
| Mechanism | Iron chelation (prevents ROS generation via Fenton reaction) + inhibition of topoisomerase IIβ in cardiomyocytes (recently identified mechanism) |
| FDA approval | Only FDA-approved cardioprotectant for anthracyclines |
| Approved indication | Patients with metastatic breast cancer who have received >300 mg/m² of doxorubicin |
| Note | Also used as an extravasation rescue agent for anthracycline infiltration |
- Fuster and Hurst's The Heart, 15th ed.; Katzung's Basic & Clinical Pharmacology
4. AMIFOSTINE - Nephrotoxicity & Xerostomia
| Property | Detail |
|---|---|
| Anticancer drug | Cisplatin; also radiation (head and neck) |
| Toxicity prevented | Cisplatin-induced nephrotoxicity; radiation-induced xerostomia |
| Mechanism | Thiophosphate prodrug - dephosphorylated by alkaline phosphatase (more active in normal vs. tumor tissue) to free thiol, which scavenges free radicals and binds alkylating species |
| Key property | Selectively protects normal tissue over tumor tissue (due to differential alkaline phosphatase activity and poorer vascular supply in tumors) |
| Note | Does NOT protect against cisplatin ototoxicity; ototoxicity is unaffected by diuresis or amifostine |
- Goodman & Gilman's; Brenner & Rector's The Kidney
5. G-CSF / GM-CSF - Myelosuppression (Neutropenia)
| Agent | Class | Drug |
|---|---|---|
| Filgrastim | G-CSF (granulocyte CSF) | Stimulates neutrophil progenitors |
| Pegfilgrastim | Long-acting G-CSF | Once-per-cycle dosing |
| Tbo-filgrastim | G-CSF biosimilar | Similar to filgrastim |
| Sargramostim | GM-CSF | Stimulates granulocyte + monocyte progenitors |
-
Use: Prevention of febrile neutropenia after myelosuppressive chemotherapy; shortening neutropenia duration post-HSCT
-
Mechanism: Binds G-CSF receptors on neutrophil progenitors → stimulates proliferation, differentiation, and phagocytic activation of mature neutrophils
-
Katzung's Basic & Clinical Pharmacology; Lippincott Illustrated Reviews
6. OPRELVEKIN (IL-11, Neumega) - Thrombocytopenia
| Property | Detail |
|---|---|
| Anticancer drug | Any myelosuppressive chemotherapy for nonmyeloid malignancy |
| Toxicity prevented | Severe thrombocytopenia (platelet count <20 × 10⁹/L) |
| Mechanism | Recombinant IL-11 stimulates megakaryocyte proliferation and platelet production |
| Use | Administer until platelet count returns to >100 × 10⁹/L |
| Major complications | Fluid retention, atrial arrhythmias, conjunctival redness |
- Goodman & Gilman's (Interleukin-11 section)
7. ALLOPURINOL / RASBURICASE - Tumor Lysis Syndrome (Hyperuricemia)
| Agent | Mechanism | Use |
|---|---|---|
| Allopurinol | Xanthine oxidase inhibitor → blocks uric acid synthesis | Prevention of hyperuricemia pre-chemotherapy; moderate TLS risk |
| Rasburicase | Recombinant urate oxidase → converts uric acid to allantoin (highly soluble) | High TLS risk (high-grade lymphoma, ALL, bulky disease); faster and more effective than allopurinol |
-
Both combined with IV hydration ± urine alkalinization
-
Rasburicase is contraindicated in G6PD deficiency (allantoin metabolite causes hemolysis)
-
Brenner & Rector's The Kidney; Murray & Nadel's Respiratory Medicine
8. Antiemetics - CINV (Chemotherapy-Induced Nausea & Vomiting)
| Drug Class | Examples | Use |
|---|---|---|
| 5-HT₃ antagonists | Ondansetron, granisetron, palonosetron | Acute CINV (first 24 h); palonosetron also covers delayed |
| NK₁ receptor antagonists | Aprepitant, fosaprepitant, netupitant | Delayed CINV (>24 h); highly emetogenic regimens |
| Corticosteroids | Dexamethasone | Synergistic with 5-HT₃ and NK₁ antagonists in all phases |
| Dopamine antagonists | Metoclopramide, haloperidol | Breakthrough CINV |
| Cannabinoids | Dronabinol, nabilone | Refractory CINV |
-
ASCO 2011 guidelines: 5-HT₃ antagonist + NK₁ antagonist + dexamethasone for highly emetogenic regimens (e.g., cisplatin)
-
Goodman & Gilman's; Miller's Anesthesia
9. Other Specific Cytoprotectants
| Drug | Protects Against | Anticancer Drug | Mechanism |
|---|---|---|---|
| Folic acid + Vitamin B12 | Hematologic/GI toxicity | Pemetrexed, pralatrexate | Replenish folate pool |
| IV hydration + NaHCO₃ | Nephrotoxicity, uric acid precipitation | Cisplatin, MTX, high-dose regimens | Dilution + urinary alkalinization |
| Methylene blue | Ifosfamide encephalopathy | Ifosfamide | Reduces chloroacetaldehyde toxicity |
| Pyridoxine (Vit B6) | Peripheral neuropathy | Isoniazid (used alongside chemo in TB) | Repletes B6 depleted by drug |
| Calcium/Magnesium infusions | Neuropathy | Oxaliplatin | May reduce acute cold-triggered neuropathy (evidence debated) |
| Liposomal doxorubicin | Cardiotoxicity | (formulation change) | Reduces peak free doxorubicin levels |
Quick Reference Summary Table
| Toxicity | Causative Drug | Protective Agent |
|---|---|---|
| Hemorrhagic cystitis | Cyclophosphamide, Ifosfamide | MESNA |
| Bone marrow/GI toxicity | Methotrexate (high dose) | Leucovorin rescue |
| Cardiotoxicity | Doxorubicin (anthracyclines) | Dexrazoxane |
| Nephrotoxicity | Cisplatin | Amifostine, forced hydration |
| Neutropenia | Any myelosuppressive agent | Filgrastim / Pegfilgrastim (G-CSF) |
| Thrombocytopenia | Any myelosuppressive agent | Oprelvekin (IL-11) |
| Hyperuricemia / TLS | Cytotoxics (esp. lymphomas) | Allopurinol / Rasburicase |
| Nausea & vomiting | Cisplatin, anthracyclines, etc. | Ondansetron, Aprepitant, Dexamethasone |
| Encephalopathy | Ifosfamide | Methylene blue |
| Hematologic/GI toxicity | Pemetrexed | Folic acid + Vit B12 |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic & Clinical Pharmacology; Lippincott Illustrated Reviews: Pharmacology; Fuster & Hurst's The Heart (15th ed.); Brenner & Rector's The Kidney; Miller's Anesthesia
whitefield's ointment in brief
Whitfield's ointment is a classic antifungal preparation containing benzoic acid + salicylic acid in a 2:1 ratio (6% + 3%), used for superficial dermatophyte infections. Benzoic acid is fungistatic; salicylic acid is keratolytic.
Searching sources...
Finding Sources
Searching the Web
Whitfield's ointment composition mechanism uses dermatology
Reading File
Reading File
Whitfield's Ointment - In Brief
Composition
| Component | Concentration | Role |
|---|---|---|
| Benzoic acid | 6% | Antifungal (fungistatic) |
| Salicylic acid | 3% | Keratolytic |
| Base | Petrolatum (soft paraffin) | Vehicle |
- Ratio of benzoic acid : salicylic acid = 2:1
- Named after Arthur Whitfield (1868-1947), a British dermatologist
- A "half-strength" version (3% benzoic acid + 1.5% salicylic acid) exists for use on sensitive skin or in children
Mechanism of Action
Benzoic acid (fungistatic component):
- Lipid-soluble weak acid that penetrates fungal cell membranes
- Disrupts fungal energy metabolism by acidifying the cytoplasm
- Acts only fungistatic (not fungicidal) - the fungus is inhibited but not killed outright
- Therefore, cure depends on complete shedding of the infected stratum corneum
Salicylic acid (keratolytic component):
- Breaks down keratin by disrupting hydrogen bonds between keratin filaments
- Promotes desquamation (peeling) of the infected stratum corneum, removing the fungal substrate
- Enhances penetration of benzoic acid into deeper layers
- Has mild antifungal properties itself
The two components work synergistically: benzoic acid inhibits the fungus while salicylic acid accelerates removal of the infected tissue.
Uses
| Primary Use | Other Uses |
|---|---|
| Tinea pedis (athlete's foot) - main indication | Tinea capitis |
| Tinea cruris (ringworm of the groin) | Tinea corporis |
| Tinea nigra (superficial black mold infection) | Erythrasma (Corynebacterium minutissimum infection) |
Important Clinical Points
- Prolonged therapy required: Because benzoic acid is only fungistatic (not fungicidal), the infection clears only after the infected stratum corneum is fully shed. Treatment must continue for several weeks to months continuously.
- Not curative acutely - the clinical endpoint is complete epidermal turnover.
- Mild local irritation may occur at the application site; a slight burning sensation is common and transient.
- Inferior to modern antifungals: Cure rates are lower compared to imidazoles (clotrimazole, miconazole), allylamines (terbinafine), or haloprogin. However, it is far cheaper and widely available, making it relevant in resource-limited settings.
- Classified as an "older/traditional" topical medication in dermatology texts - primarily of historical and practical (cost) significance.
Adverse Effects
- Mild irritation and burning at application site (transient)
- Skin peeling/scaling (expected keratolytic effect, not an adverse effect per se)
- Not suitable for inflamed, fissured, or highly macerated skin (irritation worsens)
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics (Benzoic and Salicylic Acids section); Dermatology 2-Volume Set, 5th ed. (Bolam & Griffiths) - Traditional Topical Medications table
drug interactions of amphotericin b in brief
Amphotericin B has several key interactions: additive nephrotoxicity with aminoglycosides/cisplatin, hypokalaemia potentiates digoxin toxicity, and flucytosine synergy (but also increased flucytosine toxicity). Let me get the full textbook details.
Searching sources...
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Drug Interactions of Amphotericin B - In Brief
Amphotericin B interactions are largely driven by two properties: nephrotoxicity and electrolyte depletion (especially K⁺ and Mg²⁺). Secondary interactions stem from its combination use with flucytosine, and potential antagonism with azoles.
1. Nephrotoxicity-Based Interactions (Additive/Synergistic Toxicity)
These drugs potentiate amphotericin B's renal damage - avoid concurrent use or monitor closely:
| Drug | Nature of Interaction |
|---|---|
| Aminoglycosides (gentamicin, tobramycin, amikacin) | Additive nephrotoxicity - both are directly tubulotoxic; combination markedly increases risk of acute tubular necrosis |
| Cyclosporine | Additive nephrotoxicity; both cause renal vasoconstriction and tubular damage |
| Vancomycin | Additive nephrotoxicity |
| Cisplatin | Additive nephrotoxicity |
| Foscarnet | Additive nephrotoxicity; foscarnet already causes hypokalemia and hypomagnesemia, compounding amphotericin B's electrolyte effects |
| NSAIDs | Reduce renal prostaglandin-mediated vasodilation, worsening amphotericin-induced renal hypoperfusion |
| Contrast agents (radiocontrast dye) | Cumulative nephrotoxicity |
Mitigation: Pre-hydration with 500 mL normal saline before and after infusion significantly reduces nephrotoxicity. Sodium loading is protective.
2. Electrolyte Depletion-Based Interactions
Amphotericin B causes renal tubular wasting of K⁺ and Mg²⁺, creating important downstream interactions:
| Drug | Nature of Interaction |
|---|---|
| Digoxin | Hypokalemia greatly potentiates digoxin toxicity (digoxin and K⁺ compete for the same binding site on Na⁺/K⁺ ATPase); can precipitate life-threatening arrhythmias |
| Neuromuscular blocking agents (e.g., vecuronium, rocuronium) | Hypokalemia prolongs and intensifies neuromuscular blockade |
| Class IA/III antiarrhythmics (quinidine, sotalol, amiodarone) | Hypokalemia + hypomagnesemia exacerbates QT prolongation and TdP risk |
| Corticosteroids | Both amphotericin B and corticosteroids cause K⁺ wasting - concomitant use (e.g., as premedication for infusion reactions) can worsen hypokalemia |
Management: Regular monitoring of serum K⁺ and Mg²⁺; supplement proactively during therapy.
3. Pharmacodynamic Synergism (Beneficial Interactions)
| Drug | Nature of Interaction |
|---|---|
| Flucytosine (5-FC) | Synergistic antifungal activity - amphotericin B increases fungal cell membrane permeability, allowing greater intracellular penetration of 5-FC. This combination is standard of care for cryptococcal meningitis. However: amphotericin's nephrotoxicity reduces 5-FC renal clearance, leading to 5-FC accumulation and increased bone marrow toxicity (myelosuppression, hepatotoxicity) - monitor 5-FC levels |
| Rifampin | In vitro and animal data suggest synergy vs. Aspergillus and some yeasts; clinical data limited |
| Echinocandins (caspofungin, micafungin) | Combination shows benefit in animal models of aspergillosis and candidiasis (different cell targets: membrane ergosterol vs. cell wall β-glucan); used in refractory cases |
4. Pharmacodynamic Antagonism
| Drug | Nature of Interaction |
|---|---|
| Azoles (fluconazole, itraconazole, voriconazole) | Potential antagonism - azoles inhibit ergosterol synthesis (reducing ergosterol content), which is the very target that amphotericin B must bind to exert its effect. Less ergosterol in the membrane = reduced amphotericin B efficacy. Controversial in clinical practice; generally avoid combination except specific situations (candidemia: AMB + fluconazole has some evidence of benefit) |
5. Infusion Reaction-Related Interactions
| Drug | Interaction |
|---|---|
| Corticosteroids (hydrocortisone, dexamethasone) | Used as premedication to reduce acute infusion reactions (fever, chills, rigors); however, worsen hypokalemia - use minimum effective dose |
| Antihistamines (diphenhydramine) | Co-administered to blunt infusion reactions |
| Paracetamol/antipyretics | Premedication for fever/chills |
| Meperidine (pethidine) | Used to abort rigors during infusion |
6. Physical/Chemical Incompatibility
- Adding electrolytes (saline, KCl) directly to the amphotericin B infusion solution causes the colloidal suspension to aggregate - incompatible in the same infusion bag
- Must be reconstituted only in 5% dextrose (not normal saline)
- Filters <0.22 µm remove significant drug from the infusion line
Quick Summary Table
| Interaction Type | Interacting Drug(s) | Consequence |
|---|---|---|
| Additive nephrotoxicity | Aminoglycosides, cyclosporine, vancomycin, cisplatin, foscarnet | Acute kidney injury |
| Hypokalemia potentiation | Digoxin, antiarrhythmics, NMB agents, corticosteroids | Arrhythmia, prolonged paralysis |
| Beneficial synergy | Flucytosine, echinocandins, rifampin | Enhanced antifungal activity |
| Flucytosine toxicity | 5-FC + AmpB (reduced clearance) | Myelosuppression, hepatotoxicity |
| Antagonism | Azoles | Reduced antifungal efficacy |
| Premedication interactions | Hydrocortisone | Worsened hypokalemia |
Sources: Lippincott Illustrated Reviews: Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics; Jawetz Melnick & Adelberg's Medical Microbiology 28e; Murray & Nadel's Textbook of Respiratory Medicine; Medical Microbiology 9e
This is a shared conversation. Sign in to Orris to start your own chat.